Journal info
Select Journal
Webshop Cart
Cardiology Letters Vol.29, No.4, p.240–242, 2020 |
||
Title: Je dôležité znížiť aj „Lipoproteín a“ [Lp(a)] pri sekundárnej prevencii kardiovaskulárnej morbidity a mortality? / Is it important to reduce serum levels of Lp(a) in secondary prevention of cardiovascular morbidity and mortality? | ||
Author: J. Murín, J. Bulas, M. Wavruch | ||
Abstract: Abstrakt. Ovplyvnenie sérových lipidov, osobitne LDL-Ch hypolipidemickou liečbou (statíny, prípadne s ezetipibom, v osobitných prípadoch aj PCSK9 inhibítory) redukuje kardiovaskulárnu (KV) morbiditu a mortalitu. Dnes chceme dosahovať v sekundárnej KV prevencii ešte nižšie sérové hladiny LDL-Ch a chceme to dosiahnuť aj oveľa skôr v živote pacientov. Abstract. Reduction of serum lipids, mainly of LDL-Ch level, with lipid lowering treatments (statins, event with ezetimibe and PCSK9 inhibitors in special patients) reduces cardiovascular (CV) morbidity and mortality. These days we want, in secondary CV prevention, to lower serum LDL-Ch levels even more and we also want to start with this treatment very much earlier. |
||
Keywords: Lp(a), kardiovaskulárne aterosklerotické ochorenia, PCSK9 inhibítory, redukcia KV morbidity a mortality / Lp(a), cardiovascular atherosclerotic disease, PCSK9 inhibitors, reduction of CV morbidity and mortality | ||
Published online: 15-Oct-2020 | ||
Year: 2020, Volume: 29, Issue: 4 | Page From: 240, Page To: 242 | |
doi:10.4149/Cardiol_2020_4_7 |
||
|
download file |
|